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Background
In patients with acute ischemic stroke caused by a proximal intracranial arterial 
occlusion, intraarterial treatment is highly effective for emergency revasculariza-
tion. However, proof of a beneficial effect on functional outcome is lacking.
Methods
We randomly assigned eligible patients to either intraarterial treatment plus usual 
care or usual care alone. Eligible patients had a proximal arterial occlusion in the 
anterior cerebral circulation that was confirmed on vessel imaging and that could 
be treated intraarterially within 6 hours after symptom onset. The primary out-
come was the modified Rankin scale score at 90 days; this categorical scale mea-
sures functional outcome, with scores ranging from 0 (no symptoms) to 6 (death). 
The treatment effect was estimated with ordinal logistic regression as a common 
odds ratio, adjusted for prespecified prognostic factors. The adjusted common odds 
ratio measured the likelihood that intraarterial treatment would lead to lower mod-
ified Rankin scores, as compared with usual care alone (shift analysis).
Results
We enrolled 500 patients at 16 medical centers in the Netherlands (233 assigned to in-
traarterial treatment and 267 to usual care alone). The mean age was 65 years (range, 
23 to 96), and 445 patients (89.0%) were treated with intravenous alteplase before ran-
domization. Retrievable stents were used in 190 of the 233 patients (81.5%) assigned to 
intraarterial treatment. The adjusted common odds ratio was 1.67 (95% confidence 
interval [CI], 1.21 to 2.30). There was an absolute difference of 13.5 percentage points 
(95% CI, 5.9 to 21.2) in the rate of functional independence (modified Rankin score, 
0 to 2) in favor of the intervention (32.6% vs. 19.1%). There were no significant differ-
ences in mortality or the occurrence of symptomatic intracerebral hemorrhage.
Conclusions
In patients with acute ischemic stroke caused by a proximal intracranial occlusion 
of the anterior circulation, intraarterial treatment administered within 6 hours af-
ter stroke onset was effective and safe. (Funded by the Dutch Heart Foundation and 
others; MR CLEAN Netherlands Trial Registry number, NTR1804, and Current 
Controlled Trials number, ISRCTN10888758.)
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Intravenous alteplase administered within 4.5 hours after symptom onset is the only reperfusion therapy with proven efficacy 
in patients with acute ischemic stroke.1 However, 
well-recognized limitations of this therapy in-
clude the narrow therapeutic time window and 
contraindications such as recent surgery, coagu-
lation abnormalities, and a history of intracrani-
al hemorrhage.2 Moreover, intravenous alteplase 
appears to be much less effective at opening 
proximal occlusions of the major intracranial ar-
teries, which account for more than one third of 
cases of acute anterior-circulation stroke.3,4 Early 
recanalization after intravenous alteplase is seen 
in only about one third of patients with an occlu-
sion of the internal-carotid-artery terminus,5 and 
the prognosis without revascularization is gener-
ally poor for such patients.6 For these reasons, 
intraarterial treatment is regarded as a poten-
tially important component of the therapeutic 
armamentarium.
Intraarterial therapy can be broadly divided 
into chemical dissolution of clots with locally 
delivered thrombolytic agents and clot retrieval 
or thrombectomy with mechanical devices. Al-
though early randomized trials and subsequent 
meta-analyses7 showed a benefit of treatment with 
prourokinase8,9 or urokinase,10 their results are 
not directly applicable to current decision making 
about treatment because the control groups did 
not include intravenous alteplase, and mechani-
cal approaches have largely replaced locally ap-
plied thrombolytic agents as first-line therapy.11
The neutral results of the recent randomized, 
controlled trials of intraarterial treatment have 
contributed to uncertainty regarding the efficacy 
of the catheter-based approach.12-14 Numerous 
questions have been raised concerning the design 
and conduct of these trials, including a relatively 
long interval before intraarterial treatment, the 
absence of pretreatment vascular imaging to con-
firm a proximal intracranial occlusion, and the 
limited use of third-generation mechanical throm-
bectomy devices such as retrievable stents. In the 
Multicenter Randomized Clinical Trial of Endo-
vascular Treatment for Acute Ischemic Stroke in 
the Netherlands (MR CLEAN), we assessed wheth-
er intraarterial treatment plus usual care would 
be more effective than usual care alone in patients 
with a proximal arterial occlusion in the anterior 
cerebral circulation that could be treated intra-
arterially within 6 hours after symptom onset.
Me thods
Study Design
MR CLEAN was a pragmatic, phase 3, multicenter 
clinical trial with randomized treatment-group 
assignments, open-label treatment, and blinded 
end-point evaluation. Intraarterial treatment (in-
traarterial thrombolysis, mechanical treatment, 
or both) plus usual care (which could include in-
travenous administration of alteplase) was com-
pared with usual care alone (control group) in pa-
tients with acute ischemic stroke and a proximal 
intracranial arterial occlusion of the anterior cir-
culation that was confirmed on vessel imaging.
The study protocol (available with the full text 
of this article at NEJM.org) was approved by a cen-
tral medical ethics committee and the research 
board of each participating center. All patients or 
their legal representatives provided written in-
formed consent before randomization.
Members of the executive committee and the 
local investigators designed the study, collected 
and analyzed the data, wrote the manuscript, 
and made the decision to submit the manuscript 
for publication. The authors vouch for the accu-
racy and completeness of the data and for the fidel-
ity of this report to the study protocol. The study 
sponsors were not involved in the study design, 
study conduct, protocol review, or manuscript 
preparation or review.
Patients and Participating Centers
The study was conducted at 16 centers in the 
Netherlands. Patients were 18 years of age or 
older (no upper age limit) with acute ischemic 
stroke caused by an intracranial occlusion in the 
anterior circulation artery. Initiation of intraarte-
rial treatment had to be possible within 6 hours 
after stroke onset. Eligible patients had an occlu-
sion of the distal intracranial carotid artery, mid-
dle cerebral artery (M1 or M2), or anterior cere-
bral artery (A1 or A2), established with computed 
tomographic (CT) angiography (CTA), magnetic 
resonance angiography (MRA), or digital-subtrac-
tion angiography (DSA), and a score of 2 or higher 
on the National Institutes of Health Stroke Scale 
(NIHSS; range, 0 to 42, with higher scores indi-
cating more severe neurologic deficits). Inclusion 
of patients with an additional extracranial inter-
nal-carotid-artery occlusion or dissection was left 
to the judgment of the treating physician. Detailed 
inclusion and exclusion criteria are listed in the 
A Quick Take 
is available at 
NEJM.org 
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study protocol. We did not keep a log of patients 
who were screened for eligibility.
Randomization
The randomization procedure was Web-based, with 
the use of permuted blocks. We stratified random-
ization according to medical center, use of intrave-
nous alteplase (yes or no), planned treatment 
method (mechanical or other), and stroke sever-
ity (NIHSS score of ≤14 or >14).
Intervention
Intraarterial treatment consisted of arterial cath-
eterization with a microcatheter to the level of 
occlusion and delivery of a thrombolytic agent, 
mechanical thrombectomy, or both. The method 
of intraarterial treatment was left to the discre-
tion of the local interventionist.
The use of alteplase or urokinase for intraar-
terial thrombolysis was allowed in this trial, 
with a maximum dose of 90 mg of alteplase or 
1,200,000 IU of urokinase. The dose was re-
stricted to 30 mg of alteplase or 400,000 IU of 
urokinase if intravenous alteplase was given. 
Mechanical treatment could involve thrombus re-
traction, aspiration, wire disruption, or use of a 
retrievable stent.
Only devices that had received U.S. Food and 
Drug Administration approval or a Conformité 
Européenne (CE) marking and were approved by 
the steering committee could be used in the 
trial. One or more members of each intervention 
team had to have completed at least five full 
procedures with a particular type of device.15
Outcome and Safety Measures
The primary outcome was the score on the mod-
ified Rankin scale at 90 days. The modified 
Rankin scale is a 7-point scale ranging from 0 
(no symptoms) to 6 (death). A score of 2 or less 
indicates functional independence.16
Secondary outcomes included the NIHSS 
score at 24 hours and at 5 to 7 days or discharge 
if earlier, activities of daily living measured with 
the Barthel index, and the health-related quality 
of life measured with the EuroQol Group 5-Dimen-
sion Self-Report Questionnaire at 90 days.17,18 
We examined the following prespecified dichoto-
mizations of the modified Rankin score: 0 or 1 
versus 2 to 6, 0 to 2 versus 3 to 6, and 0 to 3 versus 
4 to 6. Imaging outcomes included arterial re-
canalization measured with CTA or MRA at 24 
hours and the final infarct volume on noncon-
trast CT at 5 to 7 days.
Safety variables included hemorrhagic com-
plications, progression of ischemic stroke, new 
ischemic stroke into a different vascular territo-
ry, and death. If neurologic deterioration devel-
oped, additional neuroimaging was required. 
Symptomatic intracranial hemorrhage was de-
fined as neurologic deterioration (an increase of 
4 or more points in the score on the NIHSS) and 
evidence of intracranial hemorrhage on imaging 
studies. Local neurologists were aware of the 
treatment-group assignments and reported seri-
ous adverse events through our Web-based data-
base or by fax or e-mail.
Clinical and Radiologic Assessment
All patients underwent clinical assessment (in-
cluding determination of the NIHSS score) at 
baseline, after 24 hours, and at 5 to 7 days or at 
discharge if earlier. A single experienced trial in-
vestigator, who was unaware of the treatment-
group assignments, conducted the follow-up in-
terviews at 90 days by telephone with the patient, 
proxy, or health care provider. This interview 
provided reports for the assessment of the modi-
fied Rankin score by reviewers who remained 
unaware of the treatment-group assignments.16-18
The imaging committee evaluated the find-
ings on baseline noncontrast CT for the Alberta 
Stroke Program Early Computed Tomography 
Score (ASPECTS; range, 0 to 10, with 1 point 
subtracted for any evidence of early ischemic 
change in each defined region on the CT scan),19 
baseline vessel imaging (CTA, MRA, or DSA) for 
the location of the occlusion, and follow-up CTA 
or MRA at 24 hours for vessel recanalization. 
Recanalization was classified as complete or not 
complete and was further evaluated with the use 
of the modified Arterial Occlusive Lesion score 
(see the Supplementary Appendix, available at 
NEJM.org, for details about scales).20,21 Follow-
up CT scans obtained at 5 days were assessed for 
the presence of intracranial hemorrhage.22 All 
neuroimaging studies were evaluated by two neu-
roradiologists who were unaware of the treat-
ment-group assignments. The final infarct vol-
ume on the follow-up CT scan was assessed with 
the use of an automated, validated algorithm.23 
An independent core laboratory assessed angio-
graphic outcomes on DSA imaging, using the 
modified Thrombolysis in Cerebral Infarction 
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(TICI) score, which ranges from 0 (no reperfu-
sion) to 3 (complete reperfusion).21
Statistical Analysis
All analyses were based on the intention-to-treat 
principle. The primary effect variable was the ad-
justed common odds ratio for a shift in the direc-
tion of a better outcome on the modified Rankin 
scale; this ratio was estimated with multivariable 
ordinal logistic regression.24 We calculated an 
adjusted odds ratio for all possible cutoff values 
on the modified Rankin scale to assess the con-
sistency of effect and the plausibility of propor-
tionality of the odds ratio. The adjusted common 
odds ratio and all secondary effect variables were 
adjusted for potential imbalances in the follow-
ing major prognostic variables between the inter-
vention group and the control group: age; stroke 
severity (NIHSS score) at baseline; time from 
stroke onset to randomization; status with re-
spect to previous stroke, atrial fibrillation, and 
diabetes mellitus; and occlusion of the internal-
carotid-artery terminus (yes vs. no).25 We imput-
ed missing values of baseline variables that were 
used to adjust the regression models of treatment 
effect on primary and secondary outcomes with 
mean or mode, as applicable. No outcomes were 
imputed, except for single missing values of 
items on the NIHSS at 24 hours and at 5 to 7 days 
or discharge. Patients who died were not assigned 
NIHSS scores and were not included in analyses 
of such scores.
The adjusted and unadjusted common odds ra-
tios are reported with 95% confidence intervals to 
indicate statistical precision. Binary outcomes were 
analyzed with logistic regression and are reported 
as adjusted and unadjusted odds ratios with 95% 
confidence intervals. All P values are two-sided.
Treatment-effect modification was explored 
in prespecified subgroups of patients, defined by 
NIHSS score (2 to 15, 16 to 19, or ≥20), age (≥80 
years or <80 years), occlusion of the internal-
carotid-artery terminus (yes or no), additional 
extracranial internal-carotid-artery occlusion (yes 
or no), time from stroke onset to randomization 
(≤120 minutes or >120 minutes), and ASPECTS 
(0 to 4, 5 to 7, or 8 to 10). The statistical sig-
nificance of possible differences between sub-
groups in the treatment effect was tested with 
interaction terms. No adjustments for multiple 
tests were made. All analyses were performed 
with the use of the Stata/SE statistical package, 
version 13.1 (StataCorp).
Assuming a 10% crossover rate,26 we calcu-
lated that a sample of 500 patients (250 patients 
in each group) would yield a power of 82%, at a 
significance level of 0.05, to detect a treatment 
effect that resulted in an absolute increase of 10 
percentage points in the proportion of patients 
with a modified Rankin score of 0 to 3 in the 
intervention group as compared with the pro-
portion in the control group.
R esult s
Randomization and Baseline Characteristics
Between December 2010 and March 2014, a total 
of 502 patients underwent randomization in 16 
Dutch centers. Two patients, whose representatives 
withdrew consent immediately after randomization 
and assignment to the control group, could not be 
included in the intention-to-treat analysis.
The mean age of the 500 study participants was 
65 years (range, 23 to 96); 292 participants 
(58.4%) were men. Risk factors for a poor out-
come, clinical risk factors for stroke, and aspects 
of prerandomization treatment were evenly dis-
tributed between the two treatment groups (Table 
1, and Table S1 in the Supplementary Appendix).
Treatment Assignments and Crossovers
In total, 233 patients (46.6%) were assigned to 
the intervention group and 267 patients (53.4%) 
were assigned to the control group. One patient 
received intraarterial treatment after being as-
signed to the control group. Intraarterial treat-
ment was never initiated in 17 patients (7.3%) 
assigned to the intervention group (Fig. S1 in the 
Supplementary Appendix).
Intervention Details
Actual intraarterial therapy (with or without me-
chanical thrombectomy) was performed in 196 of 
the 233 patients in the intervention group (84.1%). 
In 88 patients (37.8%), general anesthesia was used. 
A simultaneous second revascularization proce-
dure (acute cervical carotid stenting) was per-
formed in 30 patients (12.9%).
Mechanical treatment was performed in 195 
of the 233 patients (83.7%). Retrievable stents were 
used in 190 patients (81.5%), and other devices were 
used in 5 patients (2.1%) (Table S2 in the Supple-
mentary Appendix). Additional intraarterial throm-
bolytic agents were given to 24 patients (10.3%).
Intraarterial thrombolytic agents were used 
as monotherapy in 1 of the 233 patients (0.4%). 
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Table 1. Baseline Characteristics of the 500 Patients.*
Characteristic
Intervention  
(N = 233)
Control  
(N = 267)
Age — yr
Median 65.8 65.7
Interquartile range 54.5–76.0 55.5–76.4
Male sex — no. (%) 135 (57.9) 157 (58.8)
NIHSS score†
Median (interquartile range) 17 (14–21) 18 (14–22)
Range 3–30 4–38
Location of stroke in left hemisphere — no. (%) 116 (49.8) 153 (57.3)
History of ischemic stroke — no. (%) 29 (12.4) 25 (9.4)
Atrial fibrillation — no. (%) 66 (28.3)  69 (25.8)
Diabetes mellitus — no. (%) 34 (14.6)  34 (12.7)
Prestroke modified Rankin scale score — no. (%)‡
0 190 (81.5) 214 (80.1)
1 21 (9.0)  29 (10.9)
2 12 (5.2) 13 (4.9)
>2 10 (4.3) 11 (4.1)
Systolic blood pressure — mm Hg§ 146±26.0 145±24.4
Treatment with IV alteplase — no. (%) 203 (87.1) 242 (90.6)
Time from stroke onset to start of IV alteplase — min
Median 85 87
Interquartile range 67–110 65–116
ASPECTS — median (interquartile range)¶ 9 (7–10) 9 (8–10)
Intracranial arterial occlusion — no./total no. (%)‖
Intracranial ICA  1/233 (0.4)  3/266 (1.1)
ICA with involvement of the M1 middle cerebral artery segment  59/233 (25.3)  75/266 (28.2)
M1 middle cerebral artery segment 154/233 (66.1) 165/266 (62.0)
M2 middle cerebral artery segment 18/233 (7.7) 21/266 (7.9)
A1 or A2 anterior cerebral artery segment  1/233 (0.4)  2/266 (0.8)
Extracranial ICA occlusion — no./total no. (%)‖**  75/233 (32.2)  70/266 (26.3)
Time from stroke onset to randomization — min††
Median 204 196
Interquartile range 152–251 149–266
Time from stroke onset to groin puncture — min
Median 260 NA
Interquartile range 210–313
* The intervention group was assigned to intraarterial treatment plus usual care, and the control group was assigned to 
usual care alone. Plus–minus values are means ±SD. ICA denotes internal carotid artery, IV intravenous, and NA not 
applicable.
† Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating 
more severe neurologic deficits. The NIHSS is a 15-item scale, and values for 30 of the 7500 items were missing 
(0.4%). The highest number of missing items for a single patient was 6.
‡ Scores on the modified Rankin scale of functional disability range from 0 (no symptoms) to 6 (death). A score of 2 or 
less indicates functional independence.
§ Data on systolic blood pressure at baseline were missing for one patient assigned to the control group.
¶ The Alberta Stroke Program Early Computed Tomography Score (ASPECTS) is a measure of the extent of stroke. 
Scores ranges from 0 to 10, with higher scores indicating fewer early ischemic changes. Scores were not available for 
four patients assigned to the control group: noncontrast computed tomography was not performed in one patient, 
and three patients had strokes in the territory of the anterior cerebral artery.
‖ Vessel imaging was not performed in one patient in the control group, so the level of occlusion was not known.
** Extracranial ICA occlusions were reported by local investigators.
†† Data were missing for two patients in the intervention group.
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No intervention was given in 37 patients (15.9%) 
(Fig. S1 in the Supplementary Appendix).
Primary Outcome
Data on the primary outcome (the score on the 
modified Rankin scale at 90 days) were com-
plete. There was a shift in the distribution of the 
primary-outcome scores in favor of the interven-
tion. The adjusted common odds ratio was 1.67 
(95% confidence interval [CI], 1.21 to 2.30) (Ta-
ble 2). The shift toward better outcomes in favor 
of the intervention was consistent for all catego-
ries of the modified Rankin scale, except for 
death (Fig. 1). The absolute between-group dif-
ference in the proportion of patients who were 
functionally independent (modified Rankin score, 
Table 2. Primary and Secondary Outcomes and Treatment Effects.*
Outcome
Intervention 
(N = 233)
Control  
(N = 267)
Effect  
Variable
Unadjusted  
Value (95% CI)
Adjusted  
Value (95% CI)†
Primary outcome: modified Rankin scale 
score at 90 days — median 
(interquartile range)
3 (2 to 5) 4 (3 to 5) Common  
odds ratio
1.66 (1.21 to 2.28) 1.67 (1.21 to 2.30)
Secondary outcomes
Clinical outcomes
Modified Rankin score of 0 or 1  
at 90 days — no. (%)
27 (11.6) 16 (6.0) Odds ratio 2.06 (1.08 to 3.92) 2.07 (1.07 to 4.02)
Modified Rankin score of 0–2  
at 90 days — no. (%)
76 (32.6) 51 (19.1) Odds ratio 2.05 (1.36 to 3.09) 2.16 (1.39 to 3.38)
Modified Rankin score of 0–3  
at 90 days — no. (%)
119 (51.1) 95 (35.6) Odds ratio 1.89 (1.32 to 2.71) 2.03 (1.36 to 3.03)
NIHSS score after 24 hr — median 
(interquartile range)‡
13 (6 to 20) 16 (12 to 21) Beta 2.6 (1.2 to 4.1) 2.3 (1.0 to 3.5)
NIHSS score at 5–7 days or dis-
charge — median (inter-
quartile range)§
8 (2 to 17) 14 (7 to 18) Beta 3.2 (1.7 to 4.7) 2.9 (1.5 to 4.3)
Barthel index of 19 or 20 at 90 days 
— no./total no. (%)¶
99/215 (46.0) 73/245 (29.8) Odds ratio 2.0 (1.3 to 2.9) 2.1 (1.4 to 3.2)
EQ-5D score at 90 days — median 
(interquartile range)‖
0.69 (0.33 to 0.85) 0.66 (0.30 to 0.81) Beta 0.08 (0.00 to 0.15) 0.06 (−0.01 to 0.13)
Imaging outcomes
No intracranial occlusion on fol-
low-up CT angiography — 
no./total no. (%)**
141/187 (75.4) 68/207 (32.9) Odds ratio 6.27 (4.03 to 9.74) 6.88 (4.34 to 10.94)
Final infarct volume on CT††
Patients evaluated — no. (%) 138 (59.2) 160 (59.9)
Median (interquartile range) — 
ml
49 (22 to 96) 79 (34 to 125) Beta 20 (3 to 36) 19 (3 to 34)
* CT denotes computed tomography.
† Values were adjusted for age; NIHSS score at baseline; time from stroke onset to randomization; status with respect to previous stroke, 
atrial fibrillation, and diabetes mellitus; and occlusion of the internal-carotid-artery terminus (yes vs. no).
‡ The NIHSS score was determined for survivors only. The score was not available for 20 patients: 12 died before assessment was finished, 
and 8 had missing scores.
§ The NIHSS score was determined for survivors only. The score was not available for 74 patients: 56 died before assessment was finished, 
and 18 had missing scores.
¶ The Barthel index is an ordinal scale for measuring performance of activities of daily living. Scores ranges from 0 to 20, with 0 indicating 
severe disability and 19 or 20 indicating no disability that interferes with daily activities.
‖ The EuroQoL Group 5-Dimension Self-Report Questionnaire (EQ-5D) is a standardized instrument for the measurement of health status. 
Scores range from −0.33 to 1.00, with higher scores indicating a better quality of life.
** Data for follow-up CT angiography were not available for 106 patients owing to imminent death or death (24 patients), decreased kidney 
function (13 patients), insufficient scan quality (5 patients), and other reasons (64 patients).
†† Data for final infarct volume on noncontrast CT (performed at 3 to 9 days) were missing for 202 patients because of death (52 patients), 
hemicraniectomy (21 patients), technical errors with automated assessment (14 patients), or insufficient scan quality (5 patients) or be-
cause CT was not performed for reasons other than death (110 patients).
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0 to 2) was 13.5 percentage points (95% CI, 5.9 to 
21.2) in favor of the intervention (32.6% vs. 19.1%), 
with an adjusted odds ratio of 2.16 (95% CI, 1.39 
to 3.38) (Table 2).
Secondary Outcomes
All clinical and imaging secondary outcomes fa-
vored the intervention (Table 2, and Table S3 in 
the Supplementary Appendix). The NIHSS score 
after 5 to 7 days was, on average, 2.9 points (95% 
CI, 1.5 to 4.3) lower in the intervention group 
than in the control group.
Data on recanalization after 24 hours, as-
sessed by means of CTA, were available for 394 
patients. An absence of residual occlusion at the 
target site was more common in the intervention 
group (141 of 187 patients [75.4%]) than in the 
control group (68 of 207 patients [32.9%]) (Table 
2). Data on infarct volume were available for 298 
of 500 patients; the between-group difference in 
volume (19 ml; 95% CI, 3 to 34) favored the in-
tervention group (Table 2). Good reperfusion 
(modified TICI score, 2b or 3) was achieved in 115 
of 196 patients (58.7%) in the intervention group 
(Table S4 in the Supplementary Appendix).
Safety
There was no significant between-group differ-
ence in the occurrence of serious adverse events 
during the 90-day follow-up period (P = 0.31) 
(Table 3). However, 13 of the 233 patients (5.6%) 
in the intervention group had clinical signs of a 
new ischemic stroke in a different vascular terri-
tory within 90 days, whereas only 1 of the 267 
patients (0.4%) in the control group did so. There 
was no significant difference in mortality at 7, 
30, or 90 days of follow-up.
Procedure-related complications in the inter-
vention group included embolization into new 
territories outside the target downstream terri-
tory of the occluded vessel in 20 of the 233 pa-
tients (8.6%), procedure-related vessel dissec-
tions in 4 patients (1.7%), and vessel perforations 
in 2 patients (0.9%).
Subgroup Analyses
There were no significant interactions between 
subgroups and treatment effect. The treatment 
effect remained consistent in all predefined sub-
groups, including those based on age (<80 years 
or ≥80 years), NIHSS score (2 to 15, 16 to 19, or 
≥20), and ASPECTS (0 to 4, 5 to 7, or 8 to 10) (Fig. 
S2 in the Supplementary Appendix). The point 
estimate for treatment effect in the subgroup 
with ASPECTS of 0 to 4 was close to unity but with 
a wide confidence interval (adjusted common 
odds ratio, 1.09; 95% CI, 0.14 to 8.46).
Discussion
Our results show that patients with acute ischemic 
stroke caused by a proximal intracranial arterial 
occlusion of the anterior circulation have a ben-
efit with respect to functional recovery when in-
traarterial treatment is administered within 6 hours 
after stroke onset. This treatment leads to a clin-
ically significant increase in functional indepen-
dence in daily life by 3 months, without an in-
crease in mortality.
Our findings stand in clear distinction to those 
of recent randomized, controlled trials that failed 
to show a benefit of intraarterial treatment.12,13 
Approximately 90% of patients in each treatment 
group of MR CLEAN received intravenous al-
Intervention
(N=233)
Control
(N=267)
0 20 40 60 80 100
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Modified Rankin Scale Score
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13
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16
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Figure 1. Modified Rankin Scale Scores at 90 Days in the Intention-to-Treat 
Population.
Shown is the distribution of scores on the modified Rankin scale. Scores 
range from 0 to 6, with 0 indicating no symptoms, 1 no clinically signifi-
cant disability, 2 slight disability (patient is able to look after own affairs 
without assistance but is unable to carry out all previous activities), 3 mod-
erate disability (patient requires some help but is able to walk unassisted), 
4 moderately severe disability (patient is unable to attend to bodily needs 
without assistance and unable to walk unassisted), 5 severe disability (pa-
tient requires constant nursing care and attention), and 6 death. There was 
a significant difference between the intervention group and the control 
group in the overall distribution of scores in an analysis with univariable 
ordinal regression (common odds ratio, 1.66; 95% CI, 1.21 to 2.28), as well 
as after adjustment of the treatment effect for age; National Institutes of 
Health Stroke Scale score at baseline; time from stroke onset to random-
ization; status with respect to previous stroke, atrial fibrillation, and diabe-
tes mellitus; and occlusion of the internal-carotid-artery terminus (yes vs. 
no) in an analysis with multivariable regression (adjusted common odds 
ratio, 1.67; 95% CI, 1.21 to 2.30). In the control group, only 1 patient 
(0.4%) had a modified Rankin score of 0.
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teplase, making our cohort similar to that in the 
Interventional Management of Stroke (IMS) III 
trial, in which intravenous alteplase alone was 
compared with intravenous alteplase plus intra-
arterial treatment.12 However, in the IMS III 
trial, patients had to be enrolled and undergo 
randomization within 40 minutes after the start 
of intravenous alteplase. This requirement may 
have led to the inclusion of more patients who 
had a favorable response to intravenous alteplase 
than in MR CLEAN, which had a median time 
from the start of intravenous alteplase to random-
ization that was considerably longer than the 
maximum time in the IMS III trial. It is likely that 
intraarterial treatment will not alter the natural 
history of acute ischemic stroke in the absence of 
a proximal arterial occlusion. Unlike the IMS III 
trial and the Local versus Systemic Thrombolysis 
for Acute Ischemic Stroke (SYNTHESIS Expan-
sion) trial,13 MR CLEAN required a radiologi-
cally proven intracranial occlusion for study eli-
gibility. When the IMS III trial was designed, the 
availability of CTA was still limited, and the 
presence of a proximal arterial occlusion was 
therefore uncertain in a subgroup of patients in 
that trial (47% of the study population).12
Our study benefited from the widespread 
availability of retrievable stents, which were used 
in 82% of the patients in the intervention group. 
These devices were recently shown to be supe-
rior to the first-generation Merci device for both 
revascularization and clinical outcomes.27,28
Previous trials have been criticized because 
investigators could have treated many patients 
outside the trials. This was reflected in the low 
recruitment rates in the IMS III trial and the 
Mechanical Retrieval and Recanalization of 
Stroke Clots Using Embolectomy (MR RESCUE) 
trial,14 which had an average enrollment of 1 to 
2 patients per center per year. In contrast, all 
stroke centers in the Netherlands that provided 
intraarterial treatment during the execution of 
MR CLEAN participated in the trial, and from 
2013 onward, reimbursement by insurance com-
panies required participation in a trial.
Our trial had several limitations. First, ran-
domization was slightly unbalanced, resulting in 
more patients in the control group than in the 
intervention group. This imbalance was the re-
sult of block size and multiple stratifications.
Second, the reperfusion rate in MR CLEAN 
(modified TICI score of 2b or 3, 58.7%) was 
relatively low as compared with the rates in re-
cent case series, which were 80% or higher.29,30 
However, the rate of a modified TICI score of 2b 
or 3 in the IMS III trial was 23 to 44%, depend-
ing on the location of the occlusion. The two 
recently published phase 2 trials of retrievable 
stents showed reperfusion rates of 61% and 
86%, but these rates were based on end points 
Table 3. Safety Variables and Serious Adverse Events within 90 Days  
after Randomization.
Variable
Intervention
(N = 233)
Control 
(N = 267)
no. of patients (%)
Safety variables
Death
Within 7 days 27 (11.6) 33 (12.4)
Within 30 days 44 (18.9) 49 (18.4)
Hemicraniectomy 14 (6.0) 13 (4.9)
Serious adverse events*
Any serious adverse event 110 (47.2) 113 (42.3)
Symptomatic intracerebral hemorrhage
Any type 18 (7.7) 17 (6.4)
Parenchymal hematoma†
Type 1 0 2 (0.7)
Type 2 14 (6.0) 14 (5.2)
 Hemorrhagic infarction‡
Type 1 1 (0.4) 0
Type 2 1 (0.4) 1 (0.4)
Subarachnoid hemorrhage 2 (0.9) 0
New ischemic stroke in a different  
vascular territory§
13 (5.6) 1 (0.4)
Progressive ischemic stroke 46 (19.7) 47 (17.6)
Pneumonia 25 (10.7) 41 (15.4)
Other infection 16 (6.9) 9 (3.4)
Cardiac ischemia 1 (0.4) 4 (1.5)
Extracranial hemorrhage 0 2 (0.7)
Allergic reaction 1 (0.4) 0
Other complication 22 (9.4) 33 (12.4)
* Only first events of a type are listed. Patients having multiple events of one 
type were counted once.
† For parenchymal hematoma, type 1 was defined by one or more blood clots  
in 30% or less of the infarcted area with a mild space-occupying effect, and 
type 2 was defined by blood clots in more than 30% of the infarcted area with 
a clinically significant space-occupying effect.
‡ For hemorrhagic infarction, type 1 was defined by small petechiae along the 
margins of the infarction, and type 2 was defined by more confluent petechiae 
within the infarction area.
§ P<0.001.
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of a modified TICI score of 2a to 3 and a Throm-
bolysis in Myocardial Ischemia score of 2 or 3, 
respectively.27,28 Differentiation between a modi-
fied TICI score of 2a and a score of 2b or 3 is 
difficult when lateral DSA images are not avail-
able. This applied to 15 patients in MR CLEAN, 
who were subsequently given a modified TICI 
score of 2a. This may have led to an underesti-
mation of the actual reperfusion rate among 
patients with a modified TICI score of 2b or 3.
Third, despite the positive result of this trial, 
almost 9% of the patients in the intervention 
group had embolization into new vascular ter-
ritories on DSA. A total of 30 patients (13%) 
assigned to intraarterial treatment also under-
went a simultaneous second revascularization 
procedure (acute cervical carotid stenting), and 
this complexity needs to be considered when 
interpreting our trial results.
Fourth, a relatively low proportion of patients 
in the control group had a modified Rankin score 
of 0 to 2 at the 90-day follow-up assessment. 
This may be explained by our broad inclusion 
criteria, which allowed contraindications for 
intravenous alteplase, nonresponse to intravenous 
alteplase, octogenarians and even nonagenarians, 
and patients with extracranial internal-carotid-
artery occlusions or dissections. Taken together, 
this resulted in a population with a relatively poor 
prognosis at baseline. The advantage is a wide 
generalizability of our results.
Finally, although the outcome assessment was 
blinded, patients were aware of the treatment-
group assignments, and this might have influ-
enced their opinions about their health and func-
tional condition. However, modified Rankin scores 
at 90 days were based on assessment by reviewers 
who were unaware of the treatment-group assign-
ments, to avoid biased assessments, and the re-
sults of blinded assessments of neuroimaging 
corroborated our findings.
In conclusion, we found that intraarterial 
treatment in patients with acute ischemic stroke 
caused by a proximal intracranial occlusion of 
the anterior circulation was effective and safe 
when administered within 6 hours after stroke 
onset.
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